Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay
Myriad Genetics, Inc., a leader in genetic and tumour genomic testing and precision medicine, announced that the United States Patent and Trademark Office (USPTO) issued two new patents that further advance Myriad’s ability to bring its tumour-informed, …